... and have a greater burden on the patients. The study aimed to assess the effectiveness of etanercept (ETN) monotherapy in comparison with methotrexate (MTX) monotherapy. Methods: In this prospective interventional comparative open-label study, 117 patients with psoriasis were randomized to 2 groups; 1...

... and IGA respondents in the secukinumab group were 82.8 and 71.3%, respectively, compared to placebo. Secukinumab was superior to etanercept, with risk ratios of 1.7 and 2.1, respectively. Secukinumab was generally well tolerated during the 1-year trial period. However, adverse events also occurred...

... Etanercept Adalimumab Ustekinumab Secukinumab Research Article Dermatology 2021;237:22 30 DOI: 10.1159/000504839 Received: October 2, 2019 Accepted after revision: November 16, 2019 Published online: December 19, 2019 Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience Ezgi...

...Waishu Jin; Shuqing Zhang; Yanjuan Duan Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept...

... to loss of efficacy. Therefore, safe combination treatments are sought to improve their clinical response. Objective: To assess the efficacy, safety and tolerability of the combination therapy of etanercept with fumarates versus etanercept monotherapy. Methods: Thirty-three patients with psoriasis were...

... with etanercept. Our first patient, known to have had HCV infection for 41 years, developed an HCC after 21 months of therapy with etanercept (50 mg/week). The second patient, HCV+ for 20 years, was treated for 58 months with the same therapy, and despite no signs of liver function impairment was diagnosed...

... retrospective chart review of patients receiving FAEs was performed. Results: A total of 17 cases of patients receiving FAEs combined with at least one other systemic therapy (methotrexate, acitretin, etanercept, cyclosporine, leflunomide and infliximab) to treat psoriasis or psoriatic arthritis were identified...

... of efficacy and safety. We conclude that, in the near future, biological therapy could become an essential tool in the management of cases of HS who have not previously responded to classical treatment. Hidradenitis suppurativa Infliximab Etanercept Adalimumab Ustekinumab Acne inversa Anti-tumor...

...A.L. Breton; G. Lamblin; C. Pariset; D. Jullien Increased susceptibility to infections is among the main safety concerns raised by anti-TNF-α agents. We describe two cases of cutaneous actinomycosis in patients undergoing anti-TNF-α therapy: a 49-year-old female treated with etanercept...

... with the subcutaneous anti-TNF-α agents etanercept or adalimumab as monotherapy for a long-term continuous period. Results: Efficacy results were consistent and stable over long-term observation, as expressed by mean Psoriasis Area and Severity Index (PASI) score variation, percentage of patients achieving PASI50...

...Lluís Puig; Francisco Miguel Camacho Martínez; Enrique Gimeno Carpio; Angel López-Ávila; Carmen García-Calvo Background: The efficacy of etanercept in the treatment of psoriasis has been demonstrated in several clinical trials, but information regarding results derived from prospective...

... either adalimumab, etanercept, infliximab, rituximab or ustekinumab. Results: Twenty-two HZ cases were identified [1.26% of total cohort; adalimumab: 11/1,546 patient-years, incidence rate (IR) 7.1; etanercept: 4/789 patient-years, IR 5.1; rituximab: 1/168 patient-years, IR 5.2; ustekinumab: 2/37 patient...

...Bartosz Malisiewicz; Carla Murer; Jana Pachlopnik Schmid; Lars E. French; Peter Schmid-Grendelmeier; Alexander A. Navarini Psoriasis vulgaris Eosinophilia Tumour necrosis factor α Adalimumab Etanercept 2 2 2012 © 2010 S. Karger AG, Basel 2012 Copyright / Drug Dosage...

.... Objective: To identify whether treatment with the anti-tumour-necrosis-factor antagonist etanercept is able to induce significant modulations in transcription factor and cytokine mRNA gene expressions related to the different T cell immune response polarization (Th1, Th2, Th17 and regulatory T cells, T reg...

... with treatment-resistant chronic ulcerative NL of both shins successfully treated with subcutaneous etanercept. A review of the published literature suggests that biological agents (etanercept and infliximab) should be considered as a therapeutic alternative mainly in ulcerative NL unresponsive to prior...

... successfully with etanercept (for 30 months) and then adalimumab (for 13 months and ongoing). Blanching was initially achieved with etanercept 50 mg twice a week, but suppression of periungual inflammation then required combination therapy with etanercept 50 mg twice a week and methotrexate 10 mg weekly; lower...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Adverse drug reaction Bullous pemphigoid Etanercept Tumor necrosis factor Letter...

...Kristian Reich; Siegfried Segaert; Peter Van de Kerkhof; Cis Durian; Marie Pierre Boussuge; Laurence Paolozzi; Joseph Wajdula; Robert Boggs Objective: To assess baseline patient-reported outcomes (PROs) and PRO improvement in patients with psoriasis administered etanercept 50 mg once weekly (QW...

..., these infections often have atypical presentations that may hamper prompt diagnosis. In our report of a patient on etanercept therapy for rheumatoid arthritis, the correct diagnosis was delayed because disseminated herpes zoster was clinically mimicking vasculitis. Initially assuming rheumatoid vasculitis...

...A. Costanzo; M. Talamonti; E. Botti; G. Spallone; M. Papoutsaki; S. Chimenti Background: Biological therapy for moderate to severe psoriasis includes tumour necrosis factor (TNF) blockers (infliximab, etanercept and adalimumab) and T-cell-targeting agents (efalizumab, alefacept) that act...